Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Benitec Biopharma Inc.NASDAQ: BNTC

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 49.39M shares rose 27.9% year over year, behind the +112.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.4% from the prior quarter. Over 3 fiscal years it compounded at +166.1% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +27.9% toward the trailing-twelve-month pace of +112.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
49.39M+7.4% QoQ
Last fiscal yearJun 2025
36.21M+252.4% YoY
LTMMar 2026
43.27M+112.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.9%——
1 year+252.4%——
3-year CAGR+166.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
36.21M USD
Year-over-year change
+252.4%
4-year CAGR
+144.7%

Weighted Avg Shares (Diluted) vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 weighted avg shares (diluted) of 43.27M shares is the 7th highest of the 10 companies compared; the peer median is 98.28M shares.
  • Its year-over-year change of +112.6% is the highest of 10, against a peer median of +14.7%.
  • Over three fiscal years its annual growth of +166.1% compares with a peer median of +12.4%.
BNTC Competitors Peer median
Weighted Avg Shares (Diluted) for BNTC and competitors
Company Period LTM YoY 3-year CAGR
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026237.13M +18.0%+10.7%
QSIQuantum-Si incorporatedLTM Mar 2026201.73M +31.6%+12.4%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
GALTGalectin Therapeutics Inc.LTM Mar 202664.33M +2.7%+2.5%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
XOMAXOMA Royalty Corp.LTM Mar 202617.85M +43.0%+16.4%
PRTCPureTech Health plcFY20252.41M -91.1%-56.1%
Peer median (excluding BNTC) 98.28M+14.7%+12.4%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue59K73K75K00
Cost of Revenue123K9K0343K0
Gross Profit(64K)64K75K(343K)(396K)
Gross Margin-108.5%87.7%100.0%——
Research & Development7.02M11.27M12.77M15.61M18.33M
Selling, General & Admin6.51M6.65M6.38M6.99M23.43M
Operating Expenses13.53M17.92M19.16M22.49M41.77M
Depreciation & Amortization424K392K381K343K396K
EBITDA(13.45M)(17.78M)(18.7M)(22.15M)(41.37M)
EBITDA Margin-22800.0%-24361.6%-24933.3%——
Operating Income(13.6M)(17.85M)(19.08M)(22.49M)(41.77M)
Operating Margin-23044.1%-24457.5%-25441.3%——
Interest Income000904K0
Interest Expense6K32K33K00
Other Income / Expenses(286K)(354K)(481K)739K3.85M
Income Before Tax(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Pre-Tax Margin-23528.8%-24942.5%-26082.7%——
Income Tax Expense00000
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Net Margin-23528.8%-24942.5%-26082.7%——
EPS (Basic)(27.27)(19.31)(14.12)(2.68)(1.05)
EPS (Diluted)(27.27)(19.31)(14.12)(2.68)(1.05)
Weighted Avg Shares1.01M1.92M1.39M10.26M36.21M
Weighted Avg Shares (Diluted)1.01M1.92M1.39M10.28M36.21M

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.